NYSE:ALB - Albemarle Stock Price, News, & Analysis

Albemarle trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALB."

Albemarle declared a quarterly dividend on Tuesday, October 30th. Stockholders of record on Friday, December 14th will be given a dividend of $0.335 per share on Wednesday, January 2nd. This represents a $1.34 annualized dividend and a dividend yield of 1.75%. The ex-dividend date of this dividend is Thursday, December 13th. View Albemarle's Dividend History.

Albemarle Co. (NYSE:ALB) issued its quarterly earnings results on Wednesday, November, 7th. The specialty chemicals company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.25 by $0.06. The specialty chemicals company had revenue of $778 million for the quarter, compared to analyst estimates of $796.79 million. Albemarle had a net margin of 10.44% and a return on equity of 15.39%. Albemarle's quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the business posted $1.08 earnings per share. View Albemarle's Earnings History.

Albemarle is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for Albemarle.

Albemarle updated its FY18 earnings guidance on Wednesday, November, 7th. The company provided earnings per share guidance of $5.30-5.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.39. The company issued revenue guidance of $3.3-3.5 billion, compared to the consensus revenue estimate of $3.37 billion.Albemarle also updated its FY 2018 guidance to $5.30-5.50 EPS.

19 brokers have issued 1-year price objectives for Albemarle's shares. Their forecasts range from $59.00 to $150.00. On average, they anticipate Albemarle's share price to reach $114.0321 in the next year. This suggests a possible upside of 48.8% from the stock's current price. View Analyst Price Targets for Albemarle.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albemarle in the last year. There are currently 2 sell ratings, 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Albemarle.

News coverage about ALB stock has trended somewhat negative on Friday, InfoTrie reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Albemarle earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave news coverage about the specialty chemicals company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Some companies that are related to Albemarle include Eastman Chemical (EMN), Hexcel (HXL), Sinopec Shanghai Petrochemical (SHI), PolyOne (POL), Trinseo (TSE), Rogers (ROG), AdvanSix (ASIX), Kraton (KRA), Cereplast (CERPQ), A Schulman (SHLM) and ForceField Energy (FNRG).

Albemarle's stock is owned by a variety of of institutional and retail investors. Top institutional investors include KAMES CAPITAL plc (0.50%), Scout Investments Inc. (0.22%), Personal Capital Advisors Corp (0.16%), Professional Advisory Services Inc. (0.09%), Centre Asset Management LLC (0.06%) and Beech Hill Advisors Inc. (0.02%). Company insiders that own Albemarle stock include Douglas L Maine, Karen G Narwold, Luther C Iv Kissam, Matthew Juneau and Scott Tozier. View Institutional Ownership Trends for Albemarle.

ALB stock was sold by a variety of institutional investors in the last quarter, including QCI Asset Management Inc. NY, Personal Capital Advisors Corp, Beech Hill Advisors Inc., Centre Asset Management LLC, Appleton Partners Inc. MA, Bangor Savings Bank, Intl Fcstone Inc. and Louisiana State Employees Retirement System. Company insiders that have sold Albemarle company stock in the last year include Karen G Narwold and Scott Tozier. View Insider Buying and Selling for Albemarle.

ALB stock was bought by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, DNB Asset Management AS, New England Research & Management Inc., Virtu Financial LLC, Scout Investments Inc., Hudson Valley Investment Advisors Inc. ADV, Professional Advisory Services Inc. and State of Alaska Department of Revenue. View Insider Buying and Selling for Albemarle.

Shares of ALB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ALB stock can currently be purchased for approximately $76.63.

Albemarle has a market capitalization of $7.85 billion and generates $3.07 billion in revenue each year. The specialty chemicals company earns $54.85 million in net income (profit) each year or $4.59 on an earnings per share basis. Albemarle employs 5,400 workers across the globe.

The official website for Albemarle is http://www.albemarle.com.

Albemarle's mailing address is 4350 CONGRESS STREET SUITE 700, CHARLOTTE NC, 28209. The specialty chemicals company can be reached via phone at 980-299-5700 or via email at [email protected]